Halaven (eribulin mesylate) | Injection Chemotherapy for Metastatic Breast Cancer

Halaven (eribulin mesylate) | Injection Chemotherapy for Metastatic Breast Cancer

Halaven (eribulin mesylate) | Injection Chemotherapy for Metastatic Breast Cancer

(Clics: 91;Site ajouté: Jun 11, 2015)

Description:

Halaven (eribulin mesylate) monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.